Rallybio Corporation
RLYB · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.08 | 0.05 | 0.25 | 0.04 |
| FCF Yield | -55.28% | -34.82% | -23.00% | -25.96% |
| EV / EBITDA | -0.57 | -1.52 | -2.52 | -2.25 |
| Quality | ||||
| ROIC | -22.50% | -17.84% | -17.99% | -16.98% |
| Gross Margin | 100.00% | 100.00% | 21.05% | 100.00% |
| Cash Conversion Ratio | -0.41 | 0.86 | 1.08 | 0.89 |
| Growth | ||||
| Revenue 3-Year CAGR | 876,671.92% | 912,880.61% | 946,424.70% | 859,874.76% |
| Free Cash Flow Growth | 17.89% | -3.48% | 27.19% | -30.02% |
| Safety | ||||
| Net Debt / EBITDA | 0.93 | 1.52 | 1.19 | 2.08 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | -834.00 | 7,495.71 |